Rivastigmine Tartrate Capsule
Product Images NDC 46708-065

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Rivastigmine Tartrate (NDC 46708-065). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Rivastigmine Fig1)

FDA Label Image

Figure 2 (Rivastigmine Fig2)

FDA Label Image

Figure 3 (Rivastigmine Fig3)

Figure 3 (Rivastigmine Fig3)
Not available.*
FDA Label Image

Figure 4 (Rivastigmine Fig4)

Figure 4 (Rivastigmine Fig4)
This is a chart showing the mean change from baseline in AADAS-cog rating during treatment for clinical improvement or decline. The chart is divided into 4 columns with the labels 0, 12, 18, and 26 weeks. There is not enough context to determine what exactly is being treated for.*
FDA Label Image

Figure 5 (Rivastigmine Fig5)

FDA Label Image

Figure 6 (Rivastigmine Fig6)

Figure 6 (Rivastigmine Fig6)
This appears to be a chart or graph showing the percentage of patients who experienced improvement or worsening of their condition in response to different doses of a treatment compared to a placebo. The treatment is not specified and the chart uses the CIBIC-Plus rating scale to measure improvement. Without additional context it is difficult to provide a more specific description or interpretation of the data.*
FDA Label Image

Figure 7 (Rivastigmine Figure7)

FDA Label Image

Figure 8 (Rivastigmine Figure8)

FDA Label Image

1.5 mg 30's Bottle Pack (Rivastigmine mg15)

1.5 mg 30's Bottle Pack (Rivastigmine mg15)
Each capsule of this medication contains 1.5mg of rivastigmine tartrate USP. Refer to the package insert for dosage information. The recommended storage temperature is between 15°C and 30°C. It should be kept in a tightly sealed container away from children. Produced by Alembic Pharmaceuticals Limited, the medication is sold in packs of 30 capsules and is only available on prescription. The details of the batch, expiry date, and NDC number are also provided.*
FDA Label Image

3 mg 30's Bottle Pack (Rivastigmine mg3)

3 mg 30's Bottle Pack (Rivastigmine mg3)
The text seems to be a medication label that includes the drug name RIVAStigMine, its strength of 3mg, and instructions to store at 25°C. The label also instructs to keep the medication in a tight container, away from the reach of children. The remaining text appears to include manufacturing and batch information, including the Mfg. Lic. No. and expiration date.*
FDA Label Image

4.5 mg 30's Bottle Pack (Rivastigmine mg45)

4.5 mg 30's Bottle Pack (Rivastigmine mg45)
This is a drug information for Rivastigmine Tartrate Capsules. Each capsule contains 45mg of rivastigmine base. The package insert should be referred to for dosage information. The capsules should be kept in a tight container, and stored at 25°C or with permitted excursions of 15 to 30°C. This drug is manufactured by Alembic Pharmaceuticals Limited in India. It comes in a pack of 30 capsules and requires a prescription. The Batch and Expiry dates are not available.*
FDA Label Image

6 mg 30's Bottle Pack (Rivastigmine mg6)

6 mg 30's Bottle Pack (Rivastigmine mg6)
This is a description of a medication manufactured by Alembic Pharmaceuticals Limited in Gujarat, India. The medication is available in the form of hard gelatin capsules containing 6mg of rivastigmine base, used to treat dementia. The medication should be stored at 25°C and kept in a tight container, out of the reach of children. The text also includes a batch number and expiry date.*
FDA Label Image

Structure (Rivastigmine Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.